Botox for rejuvenation of the periorbital region

Facial Plastic Surgery

Volumn 15, Issue 3, 1999, Pages 255-262

  Frankel, Andrew S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

Aesthetic surgery; Botox; Botulinum toxin

Indexed keywords

APRACLONIDINE; BOTULINUM TOXIN A;

AGING; DRUG CONTRAINDICATION; DRUG INDICATION; ESTHETIC SURGERY; FACE SURGERY; FACIAL EXPRESSION; FOLLOW UP; HEADACHE; HUMAN; MUSCLE HYPERTROPHY; MUSCLE WEAKNESS; ORBICULARIS OCULI MUSCLE; PTOSIS; REJUVENATION; REVIEW; SKIN DEFECT;

EID: 0032762857     PISSN: 07366825     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1064325     Document Type: Review

References (27)

1. Klein AW, Carruthers A. Editorial Dermatol Surg 1998;24:1167
2. Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 1981;33:155-188
3. Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 1980;212:16-21
4. Horn A, Porter JD, Evinger C. Botulinum toxin paralysis of the orbicularis oculi muscle. Types and time course of alterations in muscle structure, physiology and lid kinematics. Exp Brain Res 1993;96:39-53
5. Savino PJ, Mause M. Botulinum toxin therapy. Neurol Clin 1991;9:205
6. Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular mauscles. Invest Ophthalmol 1973;12:924
7. Brin MF, Fahn S, Moskowitz CB, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987;2:237-254
8. Brin MF, Fahn S, Moskowitz CB, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv Neurol 1988;50:599-608
9. Blitzer A, Brin MF. Laryngeal dystonia: A series with botulinum toxin therapy. Ann Otol Rhinol Laryngol 1991;100:85-90
10. Clark RP, Berris CE. Botulinum toxin: A treatment for facial asymmetry caused by facial nerve paralysis. Plast Reconstr Surg 1989;84:353
11. Carruthers J, Carruthers A. Treatment of glabellar frown lines with C. Botulinum exotoxin. J Dermatol Surg Oncol 1992;18:17-21
12. Blitzer A, Brin MF, Keen MS, Aviv JE. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg 1993;119:1018-1022
13. Frankel AS, Kamer FM. Chemical brow lift. Arch Otolaryngol Head Neck Surg 1998;124:321-323
14. Dermatol Surg (Special Issue) 1998;24:Number 11
15. Steel DH, Hoh HB, Harrad RA, Collins CR. Botulinum toxin for the temporary treatment of involutional lower lid entropion: A clinical and morphological study. Eye 1997;11:472-475
16. Carruthers J, Carruthers A. The adjunctive usage of botulinum toxin. Dermatol Surg 1998;24:1244-1247
17. Product literature (package insert) on Botox, Allergan, Inc., Irvine, CA, 1995
18. Gartlan MG, Hoffman HT. Crystalline preparation of botulinum toxin type A (Botox): Degradation in potency with storage. Otolaryngol Head Neck Surg 1993;108:135-140
19. Sloop RR, Cole BA, Escutin RO. Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use. Neurology 1997;48:249-253
20. Garcia A, Fulton JE. Cosmetic denervation of the muscles of facial expression with Botulinum toxin: A dose response study. J Dermatol Surg Oncol 1996;22:39-43
21. Klein AW. Dilution and storage of botulinum toxin. Dermatol Surg 1998;24:1179-1180
22. Jankovic J, Hallett M, eds. Therapy with Botulinum Toxin. New York: Marcel Dekker, 1994
23. Edelstein C, Shorr N, et al. Oculoplastic experience with the cosmetic use of botulinum A exotoxin. Dermatol Surg 1998;24:1208-1212
24. Burns RL. Complications of Botulinum exotoxin. Twenty-Fifth Annual Clinical and Scientific Meeting of the ASDS, Portland, Oregon, May 1998
25. Matarasso S. Complications of botulinum A exotoxin for hyperfunctional lines. Dermatol Surg 1998;24:1249-1254
26. National Institutes of Health Consensus Development Conference. Clinical use of Botulinum Toxin. 1990;8:1-20
27. Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 1996;46:26-29